Based on the provided data, I'll analyze whether CPT is overvalued through multiple valuation metrics and recent performance.
Valuation Analysis: CPT's Q4 2024 P/E ratio of 77.13x is significantly higher than previous quarters, indicating stretched valuation compared to historical levels. The EV/EBITDA ratio in Q4 2024 was not reported but showed an upward trend in previous quarters, reaching 52.74x in Q3 2024.
Financial Performance: Net income showed volatility throughout 2024, with Q3 recording a loss of $4.19 million before recovering to $40.69 million in Q4. The gross margin remained relatively stable around 61%, but ROE declined significantly from 9.02% in Q1 to 3.38% in Q4 2024.
Analyst Consensus: Recent analyst actions suggest caution. Barclays lowered their price target to $126 from $138, while maintaining a Buy rating. JP Morgan downgraded CPT to Sell with a $128 target, indicating concerns about valuation levels.
Conclusion: CPT appears overvalued at current levels due to elevated P/E multiple, declining ROE, and inconsistent earnings performance. The recent analyst downgrades and target price reductions further support this assessment. The company's deteriorating fundamentals and premium valuation multiples suggest limited upside potential at current prices.